This article was downloaded by: On: 23 January 2011 Access details: Access Details: Free Access Publisher Taylor & Francis Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37- 41 Mortimer Street, London W1T 3JH, UK



## Journal of Carbohydrate Chemistry

Publication details, including instructions for authors and subscription information: <http://www.informaworld.com/smpp/title~content=t713617200>

## Synthesis of Methyl 2,6-Dideoxy-3-C-Methyl-α-D-ribo- hexopyranoside (Methyl  $\alpha$ -D-Mycaroside), a Component of the Antitomor Agent Mithramycin

Roger W. Binkley<sup>a</sup>

<sup>a</sup> Department of Chemistry, Cleveland State University, Cleveland, Ohio

To cite this Article Binkley, Roger W.(1985) 'Synthesis of Methyl 2,6-Dideoxy-3-C-Methyl-α-D-ribo- hexopyranoside (Methyl α-D-Mycaroside), a Component of the Antitomor Agent Mithramycin', Journal of Carbohydrate Chemistry, 4: 2, 227 — 242

To link to this Article: DOI: 10.1080/07328308508058834 URL: <http://dx.doi.org/10.1080/07328308508058834>

## PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use:<http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

**J. CARBOHYDRATE CHEMISTRY,** *4(2), 227-242* (1985)

## SYNTHESIS OF METHYL  $2,6-DIDEOXY-3-C-METHYL-\alpha-D-RIBO-$

HEXOPYRANOSIDE (METHYL  $\alpha-\underline{D}-M$ YCAROSIDE), A COMPONENT

OF THE ANTITUMOR AGENT MITHRAMYCIN

Roger W. Binkley

Department of Chemistry Cleveland State University Cleveland, Ohio **44115** 

Received October **23,** *1984* - **Final** Form March **15,** <sup>1985</sup>

### ABSTRACT

Methyl  $\alpha$ -D-mannopyranoside (4) was converted into methyl 2,6-dideoxy-3-C-methyl-α-D-ribo-hexopyranoside (20) (methyl  $\alpha$ -D-mycaroside) by an efficient sequence of reactions TSchemes **1** and **3).** A similar set of reactions also was used to convert L-rhamnose (7) into methyl a-Lmycaroside (21). Attempted synthesis of methyl 2,6-dideoxy-**3-~-methyl-a-Q-arabino-hexopyranoside** *(22)* (methyl a-Dolivomycosider from methyl **6-deoxy-3-C-methyl-4-2-(2,2**  dimethylpropanoyl)-2-O-triflyl-a-<u>D-arabino</u>-hexopyranoside<br>(<u>18</u>), a compound generated during synthesis of <u>20</u>, was thwarted by a methyl migration which produced methyl 2,6 dideoxy-2-C-methyl-a-D-ribo-hexopyranoside (23).

#### INTRODUCTION

D-Mycarose (1), 2,6-dideoxy-3-C-methyl-D-ribo-hexose, is a branched-chain monosaccharide found in the antitumor agent mithramycin **(2).** Although mithramycin **(2)** is a valuable anticancer agent, its application is limited by the breadth of its antitumor spectrum and by its high toxicity.<sup>1</sup> Clinical and animal studies<sup>2</sup> as well as DNA binding site experiments<sup>3</sup> indicate that carbohydrate structure plays an essential role in the biological action of mithramycin **(2);**  consequently, carbohydrate modified mithramycin analogs may

*227* 



be more effective than the parent compound **(2)** or less toxic or both. In order to test this proposal, a source of mithramycin analogs is needed. The best possibility, at present, for obtaining these analogs is by chemical synthesis.

and its carbohydrate modified analogs consists of constructing the di- and trisaccharide portions of the molecule prior to their attachment to the aglycone. Such an approach calls for a readily available source of a D-mycarose derivative suitable for use in trisaccharide construction. If the synthesis of this D-mycarose derivative were sufficiently flexible to allow simple structural change (e.g., inversion of configuration at a selected chiral center or replacement of a hydroxyl group by fluorine), then monosaccharides structurally related to  $D$ -mycarose (1), could be synthesized and incorporated into a trisaccharide unit. In this paper a reaction sequence for generating an appropriate D-mycarose derivative is described. This synthesis has the flexibility to permit formation of branched-chain sugars structurally related to compound  $1$ . One approach to the synthesis of mithramycin **(2)** 

D-Mycarose derivatives have been synthesized in the past by several different methods. Early work involved achiral starting materials and, consequently, produced a  $\frac{n}{2}$ , L-mixture.<sup>4</sup> The first synthesis of the pure g-isomer from a chiral starting material began with -<br>methyl 2-deoxy-α-<u>D-arabino</u>-hexopyranoside.<sup>5</sup> More recently, two additional syntheses, each with its own attractive features, have been reported.<sup>6,7</sup> None of the existing synthetic schemes, however, possessed the opportunity needed for alteration of the 9-mycarose structure; therefore, the synthesis described below was developed. A useful feature of this synthesis is that it is easily adapted to generate L-mycarose derivatives also.

### RESULTS AND DISCUSSION

The first objective of this study was to convert methyl  $\alpha$ -D-mannopyranoside (4) into methyl 2-0-benzoyl-**6-deoxy-4-~-(2,2-dimethylpropanoyl)-a-~-mannopyranoside**  *(5)* (Scheme 1). One reason compound *5* was selected as a target molecule was that its enantiomer (5) previously had been synthesized (in 60% overall yield, Scheme **2)**  from 6-deoxy-L-mannose (7, L-rhamnose); <sup>8</sup> therefore, once compounds *5* and *6* had been obtained, synthesis of enantiomerically pure D- or L-mycarose derivatives would follow the same pathway. Also, since L-rhamnose (7) and methyl  $\alpha$ -**Q**-mannopyranoside (4) are commercially available inexpensive compounds, they represent excellent starting materials for the synthesis of D- and L-mycarose derivatives.

The synthesis of compound *5* began with the reaction of methyl  $\alpha$ -D-mannopyranoside (4) and tosyl chloride at -20 °C to give methyl 6-0-tosyl-a-D-mannopyranoside (8). When 8 was treated with  $\alpha$ ,  $\alpha$ -dimethoxytoluene according to the Evans procedure,  $9$  it was converted into an inseparable mixture of methyl 2,3-0-benzylidene- $(R \text{ and } S) - 6 - Q - \text{cos}y1 - \alpha - Q - \text{mann}oyr$  anosides (9 and  $10$ ).

**Scheme 1** 



-<br>This mixture (<u>9</u> and <u>10</u>) reacted with lithium triethyl-This mixture (<u>9</u> and <u>10</u>) reacted with lithium trieth<sub>!</sub><br>borohydride (LTBH), according to a method recently developed by Baer and Hanna,  $10$  to give the desired deoxy sugars 11 and *12.* Although these compounds were separable, further reaction of individual compounds offered no advantage over reaction of the mixture itself. Esterification of the mixture (11 and 12) with pivaloyl chloride followed by irradiation in the presence of - N-bromosuccinimide and water gave compound **2** in **40%**  overall yield from methyl a-Q-mannopyranoside **(A).**  Ring-opening of benzylidene acetals such as 11 and *12*  under these conditions has been found to be regioselective. $8$ benzoyloxy group axial and the hydroxy group equatorial. The favored conformer of the product has the

Two methods were used for the oxidation of compound *5.* The first of these involved esterification with pyruvoyl chloride followed by irradiation of the pyruvate ester to give methyl **2-2-benzoyl-6-deoxy-4-2-**  (2,2-dimethylpropanoyl)-a-D-arabino-hexopyranosid-3-ulose (13) in 73% yield (Scheme 3). **A** second method consisted of reaction of *5* with pyridinium chlorochromate in the presence of molecular sieve. The pyridinium chlorochromate oxidation took place in higher yield **(87%)** than pyruvate photolysis and was considerably faster for conversion of large quantities of material. The primary disadvantages to chromate oxidation were that chromatography was necessary to remove the black, tarry chromium salts which formed and that epimerization at C-2 in the oxidation product 13 took place. The epimerization process was suppressed by the addition of sodium acetate to the reaction mixture prior to introduction of the oxidizing agent.

carbonyl compound 13 introduced the methyl branch at C-3 and also removed benzoyl groups from some molecules. Since deprotection of 0-2 was the next step in the sequence, complete removal of the benzoyl group was accomplished by dissolving the product mixture from the Grignard reaction in methanol and adding a strongly basic ion exchange resin. The pivaloyl group was unaffected by these reaction conditions; in fact, this protecting group was chosen so that regioselective debenzoylation could be accomplished at this stage in the synthesis. **Some** of the **major** product from the deprotection process crystallized from the reaction mixture. Chromatography of the residue yielded more of the major product **(67%**  total yield) and a minor product (10%). The NMR spectra of these compounds (Tables 1 and 2) indicated chat they were the  $C-3$  epimers  $15$  and  $16$ ; however, without further Reaction of methyl magnesium iodide with the





information it could not be determined which of these two was the major product.

reaction) with triflic anhydride at room temperature resulted in rapid, quantitative formation of methyl 2,3-anhydro-6-deoxy-3-C-methyl-4-O-(2,2-dimethyl**propanoy1)-a-g-allopyranoside** *(17).* This procedure represents a mild method for epoxide formation. Epoxide formation in this case established 15 as the major product from the Grignard reaction since only 15 (and not **16)** was capable of three-membered ring formation under these conditions. Reaction of <u>16</u> with triflic anhydride produced the expected 2-2-triflyl compound 18 (Scheme **4).**  Treatment of the major product (from the Grignard

Reaction of the anhydro sugar IJ with an equal molar amount of lithium triethylborohydride (LTBH) opened the epoxide ring to give the partially protected D-mycarose derivative l9, the compound desired for future use in the mithramycin trisaccharide synthesis. (Treatment of 17 with other nucleophiles should allow formation of a



 $\widehat{p}$ 

**1.24** 

**1.27** 

**1.25** 

**1.24** 

**1.25** 

**1.23** 

**1.25** 

# **Table 2. 41.39 -67 69 76.59 62.67 17.23 54.92 <sup>20</sup>**-



،<br>نەن ئەن

Assignments for a particular compound interchanged.<br>Additional absorptions at 166.39, 129.68, 129.93, 128.53, and 133.39 ppm.<br>Additional absorptions at 164.63, 135.93, 133.58, 129.84, and 128.41 ppm.<br>Additional absorption

variety of 2-substituted compounds related to D-mycarose.) Reaction of *17* with excess lithium triethylborohydride opened the epoxide ring and removed the pivaloyl. group to give methyl  $\alpha$ -D-mycaroside 20 in 96% yield. This reaction confirmed the stereochemical assignment made to compound <u>15</u>. The overall yield of methyl  $\alpha$ -<u>D</u>mycaroside (20) from methyl a-D-mannopyranoside (4) was **22%.** 

Methyl  $\alpha$ -L-mycaroside (21), the enantiomer of 20, also was synthesized. This synthesis began with the previously reported conversion of  $L$ -rhamnose (7) into methyl 2-0-benzoyl-6-deoxy-4-0-(2,2-dimethylpropanoyl)- $\alpha$ -L-mannopyranoside (6).<sup>8</sup> It was completed by conducting the sequence of reactions shown in Scheme **3** using compound *6,* the enantiomer of *5,* as the starting material. The L-rhamnose  $(7)$  to methyl  $\alpha$ -L-mycaroside  $(21)$ transformation took place in **31%** overall yield.

The final experiment conducted involved the triflate 18. Treatment of sulfonates, such as compounds - *9* and Id, with lithium triethylborohydride (LTBH) produces in some cases the corresponding deoxy sugars **.I1**  The possiblity existed, therefore, that treatment of the<br>2-Q-triflyl compound 18 with LTBH would produce methyl 2,6-dideoxy-3-C-methyl-a-D-arabino-hexopyranoside (22) (methyl a-D-olivomycoside), the C-3 epimer of 20. When 18 was treated with LTBH, a 2,6-dideoxy sugar was formed; however, rather than the expected product 22, the rearranged methyl **2,6-dideoxy-2-C-methyl-a-Q-ribo-hexo-** - pyranoside *(23)* was produced. A proposed mechanism for this rearrangement is shown in Scheme **4.** 

### E XPERI MENTAL

General Information.  $1_H$  and  $13_C$  NMR spectra were obtained from a Varian FT-80A spectrometer. Preparative liquid chromatography was conducted using a Waters Prep LC/SYSTEM 500A. Mass spectra were determined



Scheme 4

with a Finnigan 1015-D spectrometer with methane as a reagent gas and an ionizing voltage of 150 eV.

deoxy-a-D-mannopyranosides (11 and 12). The procedure described here for introduction of the benzylidene group is a modification of that used by Evans<sup>9</sup> to synthesize  $methyl 4,6-0-benzylidene-q-2-glucopyranoside. \nMethyl \n $\frac{1}{2}$$  $6-0-tosyl-\alpha-D-\text{mannopy}$ ranoside<sup>12</sup> (4) (36 g, 0.10 mol) and  $16.7$  *g*  $(16.5$  mL, 0.11 mol) of  $\alpha, \alpha$ -dimethoxytoluene were dissolved in 200 mL of N,N-dimethylformamide (DMF) containing 0.5 g of p-toluenesulfonic acid monohydrate. The flask was attached to **a** rotary evaporator and evacuated while being heated. When the temperature reached **90 OC,** much of the DMF and other volatile material had distilled. Pyridine (2 mL) was added and the reaction mixture was placed under vacuum using a mechanical pump and held at **50** *OC* until all volatile materials had been removed. The portion of the residue which was soluble in ethyl ether was separated and the ether was distilled to give 36.9 g of material. The lH and **13C NMR** spectra of this material indicated it to be a mixture of benzyli-Synthesis of Methyl 3,4-O-Benzylidene-(S and R)-6dene acetals; however, since these compounds could not be separated by chromatography, they were used directly in the next reaction.

The procedure described in this paragraph for formation of the 6-deoxy compounds 11 and *12* is essentially that used by Baer and Hanna.<sup>13</sup> The mixture of benzylidene acetals (36.9 q) was dissolved in 150 mL of tetrahydrofuran and the reaction flask was purged with nitrogen while 300 mL of a 1.0 **M** solution of lithium triethylborohydride<sup>14</sup> (LTBH) in tetrahydrofuran was added in a dropwise manner. The reaction mixture was refluxed for 30 min and then allowed to cool to room temperature. The excess hydride reagent was destroyed by dropwise addition of 20 mL of methanol. The reaction mixture was poured into 400 mL of ice-water and 100 mL of 30% H<sub>2</sub>O<sub>2</sub> was added slowly with stirring and cooling. The stirring was continued for 2 h and then the reaction mixture was extracted with three 300 mL portions of  $CH_2Cl_2$ . The solvent was distilled to give 21.8 g (0.081 mol, 80% from **4)** of a **1:l** mixture of methyl 3,4- - O-benzylidene-(2 and **R)-6-deoxy-a-P-mannopyranoside** - *(2*  and *12).* **A** 0.5 g sample of this mixture was chromatographed on a 2.5 x 20 cm column of 240-400 mesh silica gel using 1:lO ethyl acetate-toluene to give pure samples of 11 and *12.* These compounds (11 and *12)* were identical in **13C** and 1H **NMR** spectra to those prepared independently by the benzylidenation of methyl 6-deoxya-B-mannopyranoside - . **l5** 

**dimethylpropanoyl)-a-P-mannopyrannopyranoside** (5). The esterification of the mixture of 11 and *12* and the reaction of these esters with N-bromosuccinimide and water to give *5* was conducted according to the procedure used to prepare **5,8** the enantiomer of *5.* The 1H and 13C **NMR** spectra €or **5** are given in Tables 1 and 2, respectively, and are identical to those previously reported<sup>8</sup> Synthesis of Methyl **2-O-Benzoyl-6-deoxy-4-0-(2,2**  for *6.* 

### Synthesis of Methyl **2-O-Benzoyl-6-deoxy-4-0-(2,2**  dimethylpropanoyl)-a-D-arabino-hexopyranosid-3-ulose (13).

solved in 300 mL of dry CH<sub>2</sub>Cl<sub>2</sub>. To this stirred, cooled (20 "C) solution was added 10 g (0.12 mol) of sodium acetate and 54 g (.25 mol) of pyridinium chlorochromate. The reaction mixture became dark colored after a few min. After two h, the reaction mixture was filtered and the filtrate passed through a 5 x 20 cm column of silica gel by eluting with **1:l** ethyl ether-methylene chloride. This process removed the black material. Concentration of the reaction mixture under reduced pressure gave **38** g (0.10 mol, **87%)** of methyl **2-2-benzoyl-6-deoxy-4-2-** (2,2 dimethylpropanoyl)-a-D-arabino-hexopyranosid-3-ulose (13), which did not crystallize. Compound 13 was identified on the basis of its **1H** NMR (Table 1) and I3C **NMR** (Table 2) spectra. Anal. Calcd for CigH2407: C, 62.62; H, 6.64. Found: C, 62.41; H, 6.62. Procedure A. Compound *5* (44 g, 0.12 mol) was dis-

Procedure B. Compound  $\frac{5}{2}$  (2.53 g, 0.69 x 10<sup>-2</sup> mmol) was dissolved in 50 mL of  $CH_2Cl_2$  containing 5 mL of pyridine. Pyruvoyl chloride (1.5 mL) in 10 mL of CH<sub>2</sub>Cl<sub>2</sub> was added to the rapidly stirred, cooled (ice-bath) sugar solution. After addition was complete, the reaction mixture was allowed to stand for 3 h at room temperature and then 200 mL of hexane was added slowly. This solution was filtered to remove the precipitated material. The solvent was distilled from the filtrate to leave a yellow residue. This residue was extracted with two 250 mL portions of hexane. The hexane was distilled to leave a pale yellow syrup which was dissolved in 500 mL of benzene. This solution was purged with  $N_2$  for 1 h and then irradiated for 5 h. The benzene was distilled and the residue (brown) was extracted with two 100 mL portions of hexane. The hexane was distilled to give **1.83** g (0.50 x 10'2 mol, **73%)** of compound 13.

Synthesis of Methyl **6-Deoxy-3-C-methy1-4-0-(2,2 dimethylpropanoy1)-a-D-altropyranoside** (15) and Methyl **6-Deoxy-3-C-meth~l-4-0-(2,2-dimethylpropanoyl)-a-~**  mannopyranoside (16). Compound 13 (38 g, 0.10 mol) was dissolved in 500 mL of anhydrous ethyl ether and 50 mL of a 3.0 M solution of methyl magnesium iodide<sup>14</sup> was added at such a rate that the solvent gently refluxed. After the Grignard addition was complete, the reaction mixture stood for 2 h and then 200 mL of H20 was added (slowly at first). Dilute (5%) hydrochloric acid was added with stirring until the precipitate just dissolved. (The solution was still basic.) The phases were separated and the aqueous phase was washed with an equal volume of ethyl ether. The organic extracts were combined and passed through a 5 x 20 cm column of silica gel. The ether was evaporated and the residue was dissolved in 200 mL of methanol containing 50 g of Baker ANGA-542 ion exchange resin (strong base) and stirred for 2 h. The solution was filtered and the solvent distilled. The residue was dissolved in the minimum amount of **1:l**  ethyl acetate-toluene and allowed to stand until crystallization was complete. This produced 15.4 g (5.57 x  $10^{-2}$  mol) of 6-deoxy-3-C-methyl-4-0-(2,2-dimethylpropanoyl) - $\alpha$  - $\mathbb{D}$ -altropyranoside (15), mp 140-142 °C. Anal. Calcd for C<sub>13</sub>H<sub>24</sub>O<sub>6</sub>: C, 56.50; H, 8.75. Found: C, 56.69; H, 8.86. The **IH** and I3C NMR spectra are in Tables 1 and 2, respectively.

ed using a Waters Prep **LC/SYSTEM 500 A** with **1:l** tolueneethyl acetate as the solvent. This gave an additional 3.1 g of 15 and 2.7 g of methyl 6-deoxy-3-C-methyl-4-O- $(2, 2$ -dimethylpropanoyl)-α-p-mannopyranoside (16), a compound which failed to crystallize. Anal. Calcd for  $C_1$ 3H<sub>24</sub>O<sub>6</sub>: C, 56.50; H, 8.75. Found: C, 56.69; H, 8.50. The  $1_H$  and  $13_C$  NMR spectra of  $16$  are found in Tables 1 and 2, respectively. The residue after crystallization was chromatograph-

Synthesis of Methyl **2,3-Anhydro-6-deoxy-3-C**methyl-4-0-(2,2-dimethylpropanoyl)-α-D-allopyranoside (17). Compound 15 (4.40 9, 1.59 x 10'2 mol) was dissolved in 50 mL of  $CH_2Cl_2$  containing 5 mL of pyridine. This solution was cooled to  $-20$  °C and 3.4 mL (5.7 g, 2.0 x 10<sup>-2</sup> mol) of triflic anhydride was added dropwise with stirring. The reaction mixture warmed to room temperature over a period of 4 **h.** Tlc analysis showed that the starting material had reacted completely. Water (20 mL) was added and the stirring continued for 15 min. The layers were separated and the aqueous layer extracted with 50 mL of CH<sub>2</sub>CL<sub>2</sub>. The organic extracts were combined and the solvent evaporated under reduced pressure to give 3.9 g  $(1.5 \times 10^{-2} \text{ mol}$ , 94%) of methyl 2,3-anhydro- $6$ -deoxy-3-C-methyl-4-O-(2,2-dimethylpropanoyl)-a-D-allopyranoside (17), mp 52.5-54.0 °C. Anal. Calcd for C13H2205: C, 60.44; H, 8.59. Found: 60.15, H, 8.70. NMR spectra are given in Tables 1 and 2.

(2,2-dimethylpropanoyl)-a-P-ribo-hexopyranoside (19). Compound 17 (3.69 g, 1.50 x 10<sup>-2</sup> mol) was dissolved in 50 mL of tetrahydrofuran (THF) under nitrogen and 20 mL of a 1 M solution of lithium triethylborohydride (LTBH) in THF was added slowly. After stirring for 15 min, 5 mL of methanol was added slowly. The reaction mixture was poured into 400 mL of ice-water and 10 mL of  $H_2O_2$  was added with rapid stirring. **After** 15 min, the **aqueous**  solution was extracted with CHCl<sub>3</sub> (3 x 200 mL). The solvent was distilled from the combined CHCl3 extracts to give 3.7 *g* (1.5 x 10<sup>-2</sup> mol) of compound 19, mp 73-75 °C.  $1_H$  and  $13_C$  NMR spectra are given in Tables 1 and 2, respectively. Anal. Calcd for  $C_{1,3}H_{2,4}O_5$ : C, 59.98; H, 9.29. Found: C, 59.91; H, 9.25. Synthesis of Methyl **2,6-Dideoxy-3-C-methyl-4-0-** 

Synthesis of Methyl 2,6-Dideoxy-3-C-methyl-a-Dribo-hexopyranoside (20, methyl  $\alpha$ -D-mycaroside). Compound *17* (18.1 g, 6.96 x 10-2 mol) was treated with LTBH in the same manner as was used for the synthesis of

### ANTITUMOR AGENT MITHRAMYCIN *24* 1

compounds 11 and 12 (the Baer and Hanna procedure<sup>10</sup>) to give 11.8 g  $(6.68 \times 10^{-2} \text{ mol}, 968)$  of methyl  $\alpha-\underline{D}$ mycaroside (20), mp 56-57.5 °C (lit.<sup>6</sup> 56-58 °C), identical in IH NMR spectrum with that reported in the literature.<sup>16</sup>

Synthesis of Methyl 2,6-Dideoxy-2-C-methyl-a-Dribo-hexopyranoside (23). Compound 18 (1.1 g, 4.5 **<sup>x</sup>**  $10^{-3}$  mol) was dissolved in 20 mL of CH<sub>2</sub>C1<sub>2</sub> containing 3 mL pyridine. The solution was cooled to  $-20$  °C and 2.0 mL of triflic anhydride was added with stirring in a dropwise manner. The reaction mixture warmed to room temperature over a period of 2 h. Water (20 mL) was added and the stirring continued for 15 min. The layers were separated and the aqueous layer extracted with 50 mL of CH<sub>2</sub>Cl<sub>2</sub>. The organic extracts were combined and the solvent evaporated under reduced pressure. The residue then was stirred with 125 mL of hexane and the solution decanted from the residue. The hexane was evaporated under reduced pressure to give 1.8 g  $(4.4 \times 10^{-3} \text{ mol})$  of methyl 6-deoxy-3-C-methyl-4-O-(2,2-dimethylpropanoyl)-2-0-triflyl-a-D-arabino-hexopyranoside (18), mp 114-115 °C. The  $l$ H and  $l$ 3C NMR spectra for 18 are given in Tables 1 and 2; however, this compound was unstable and generally was used immediately after preparation.

same manner as was used for the synthesis of compounds 11 and 12 (the Baer and Hanna procedure<sup>10</sup>) to give 0.70 g (3.9 x 10<sup>-3</sup> mol, 88%) of methyl 2,6-dideoxy-2-<u>C</u>-<br>methyl-a-<u>D-ribo</u>-hexopyranoside (<u>23</u>), mp 110-112 °C. Anal. Calcd for  $C_8H_16O_4$ : C, 54.53; H, 9.15. Found: C, 54.29; H, 9.01. The 1H and **13C** NMR spectra are given in Tables 1 and **2,** respectively. Compound 18 (1.8 9) was treated with LTBH in the

### ACKNOWLEDGMENT

The author wishes to thank the Standard Oil Company (Ohio) for support of this work.

### REFERENCES

- EFERENCES<br>1. M. Slavik and S. K. Carter, <u>Adv</u>. <u>Pharmacol</u>.<br><u>Chemother</u>., <u>12</u>, 1 (1975).
- **2.** Reference 1, pp. **8-10.**
- **3. M.** W. Van Dyke and P. B. Dervan, Biochem., *22,*  **2373 (1983).**
- **4.** D. M. Lemal, P. D. Pacht, and R. B. Woodward, Tetrahedron, **18** , **1275 (1962).**
- **5. B. Flaherty, W. G. Overend, and N. R. Williams, <u>J</u>. Chem. Soc. (C), 398 (1966).**
- **6.** J. Thiem and J. Elvers, Chem. Ber., 114, **<sup>1442</sup> (1981).**
- **7. I.** Dyong and G. Schulte, Chem. Ber., 114, **<sup>1484</sup> (1981).**
- **8.** R. W. Binkley, G. **S.** Goewey, and J. C. Johnston, - J. *Org.* Chem., 49, **992 (1984).**
- **9. M.** E. Evans, Methods Carbohydr. Chem., *8,* **313 (1980).**
- **10.** H. H. Baer and H. R. Hanna, Carbohydr. *g., 110,*  **19 (1982).**
- 11. H. H. Baer and D. J. Astles, Carbohydr. Res., 126, **343 (1984).**
- **12. M.** Haque and A. Freestone, **2.** Chem. **SOC.** Perkin Trans. *g,* **1509 (1977).**
- **13.** Reference 10, p. **33.**
- 14. Aldrich Chemical Company.
- **15.** C. Monneret, **J.** C. Florent, and Y. Chapleur, C. *E-*Helbd. Seances Acad. Sci. Ser. *c., 285,* **587 (1977).**
- **16.** J. Thiem and J. Elvers , Chem. Ber. , 111, **<sup>3515</sup> (1978).**